Trials / Completed
CompletedNCT03170193
AMG 529 First in Human Study
A Phase 1, Randomized, Double-blind, Placebo-controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 529 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
A study to assess the safety and tolerability of AMG 529 following single, ascending doses administered subcutaneously (SC) or intravenously (IV) in healthy adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 529 | Ascending single doses of AMG 529 by subcutaneous (SC) or intravenous (IV) injection |
| DRUG | Placebo | Single doses of matching placebo by SC or IV injection |
Timeline
- Start date
- 2017-05-15
- Primary completion
- 2017-11-17
- Completion
- 2017-11-17
- First posted
- 2017-05-30
- Last updated
- 2019-07-05
- Results posted
- 2019-07-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03170193. Inclusion in this directory is not an endorsement.